Savara Inc. (SVRA) Says FDA Will Miss Molgramostim BLA Date
Savara Inc. (SVRA) announced the FDA will miss the November 22, 2026 PDUFA target date for its molgramostim BLA for autoimmune PAP. The review is ongoing, but no revised action date was provided. This is a regulatory timing setback for Savara's lead program.
How this was made

The 30-second read
Why it matters
The missed PDUFA target introduces uncertainty about the approval timeline, which can depress the stock until a new date is set.
Market read
Regulatory timing news for a small‑cap biotech is highly relevant to traders with exposure to SVRA or the broader rare‑disease sector.
What to watch
Potential for accelerated review if additional data are submitted; market may have over‑reacted to the timing notice.
Background
Savara Inc. (SVRA) is a clinical‑stage biotech focused on rare lung diseases. Molgramostim is its lead candidate for autoimmune pulmonary alveolar proteinosis.
Ticker impact
FDA announced it will not meet the Nov 22, 2026 PDUFA target for Savara's molgramostim BLA, creating a regulatory timing setback.
likely downward pressure as investors price in the extended review timeline
Regulatory timing delays for a biotech's pivotal BLA are material and often trigger short-term sell‑offs.
Market effects
Biotech sector may see heightened scrutiny on pending BLAs, modestly affecting peer valuations.
U.S. biotech investors likely adjust positions; limited broader market effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If the FDA ultimately grants approval, the delay could be a buying opportunity at a lower price.
Key entities
- CompanySavara Inc.
Biotech developer of molgramostim.
- RegulatorFDA
U.S. Food and Drug Administration overseeing the BLA review.

